Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction

Atherosclerosis

Volumn 203, Issue 1, 2009, Pages 201-205

  van Minkelen, Rick ^a   Wettinger, Stephanie Bezzina ^b,c   de Visser, Marieke C H ^a   Vos, Hans L ^a   Reitsma, Pieter H ^a,b   Rosendaal, Frits R ^a   Bertina, Rogier M ^a   Doggen, Carine J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MALTA   (Malta)

Author keywords

Haplotypes; Inflammation; Interleukin 1 receptor antagonist; mRNA levels; Myocardial infarction; Risk factors

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MESSENGER RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; IL1RN GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RNA, MESSENGER; VENOUS THROMBOSIS;

EID: 60649089245     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.06.029     Document Type: Article

References (33)

1. Dinarello C.A. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 (2002) S1-S13
2. Dinarello C.A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16 (1998) 457-499
3. Tousoulis D., Davies G., Stefanadis C., Toutouzas P., and Ambrose J.A. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89 (2003) 993-997
4. Croce K., and Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 14 (2007) 55-61
5. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematologica 85 (2000) 967-972
6. Esmon C.T. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillières Clin Haematol 7 (1994) 453-468
7. Orbe J., Chorda C., Montes R., and Paramo J.A. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1 alpha. Haematologica 84 (1999) 306-311
8. Bochner B.S., Luscinskas F.W., Gimbrone Jr. M.A., et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 173 (1991) 1553-1557
9. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
10. van Minkelen R., de Visser M.C.H., Houwing-Duistermaat J.J., Vos H.L., Bertina R.M., and Rosendaal F.R. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 27 (2007) 1486-1491
11. Francis S.E., Camp N.J., Dewberry R.M., et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 99 (1999) 861-866
12. Iacoviello L., Donati M.B., and Gattone M. Possible different involvement of interleukin-1 receptor antagonist gene polymorphism in coronary single vessel disease and myocardial infarction. Circulation 101 (2000) E193
13. Vohnout B., Di Castelnuovo A., Trotta R., et al. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haematologica 88 (2003) 54-60
14. Zee R.Y., Lunze K., Lindpaintner K., and Ridker P.M. A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost 86 (2001) 1141-1143
15. Nicklin M.J., Hughes D.E., Barton J.L., Ure J.M., and Duff G.W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191 (2000) 303-312
16. Isoda K., Sawada S., Ayaori M., et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 280 (2005) 7002-7009
17. Doggen C.J.M., Manger Cats V., Bertina R.M., and Rosendaal F.R. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97 (1998) 1037-1041
18. Doggen C.J.M., Bertina R.M., Manger Cats V., and Rosendaal F.R. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 110 (2000) 935-938
19. Doggen C.J.M., Berckmans R.J., Sturk A., Manger Cats V., and Rosendaal F.R. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med 248 (2000) 406-414
20. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., and van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28 (1990) 495-503
21. Nickerson DA. SeattleSNPs. NHLBI Program for Genomic Applications, UW-FHCRC, Seattle, USA. http://pga.gs.washington.edu [accessed 5.04.07].
22. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14 (1999) 143-149
23. Bezzina Wettinger S., Doggen C.J.M., Spek C.A., Rosendaal F.R., and Reitsma P.H. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood 105 (2005) 2000-2006
24. Stram D.O., Haiman C.A., Hirschhorn J.N., et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55 (2003) 27-36
25. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 19 (1955) 251-253
26. Zee R.Y., Hennessey H., Michaud S.E., and Ridker P.M. Genetic variants within the interleukin-1 gene cluster, and risk of incident myocardial infarction, and ischemic stroke: a nested case-control approach. Atherosclerosis 201 (2008) 124-129
27. Tarlow J.K., Blakemore A.I., Lennard A., et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91 (1993) 403-404
28. Witkin S.S., Gerber S., and Ledger W.J. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34 (2002) 204-209
29. Tolusso B., Pietrapertosa D., Morelli A., et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 7 (2006) 683-695
30. Hurme M., and Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 28 (1998) 2598-2602
31. Rafiq S., Stevens K., Hurst A.J., et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 8 (2007) 344-351
32. Danis V.A., Millington M., Hyland V.J., and Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99 (1995) 303-310
33. Vamvakopoulos J., Green C., and Metcalfe S. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32 (2002) 2988-2996